A global study analyzing over 30 million FDA reports found Wegovy users had a 4.74-fold higher ION risk than Ozempic users, with men facing greater risk than women.
The study, published in the British Journal of Ophthalmology, suggests the higher dose in Wegovy may drive this association, while other GLP-1 drugs showed no significant ION signal.
Researchers emphasize the need for prospective studies to confirm these findings, noting limitations such as reporting bias and lack of clinical detail; ION remains a rare but serious adverse event.
Could Wegovy's higher dosage be the key factor linking it to 'eye stroke' events?
Is Wegovy's promise of dramatic weight loss worth the rare risk of sudden blindness?
Why do major studies on Wegovy and vision loss offer completely conflicting results?
With mixed signals from research, should regulators issue stronger warnings about Wegovy?
How can patients tell if blurred vision is a minor side effect or a sign of permanent damage?